diaDexus just raised $9.2 million in sixth-round funding from Scale Venture Partners, GlaxoSithKline and Baker Brothers Advisors, according to peHUB. The company's first and only product, the PLAC Test, is used to detect early indicators of risk for heart attack and stroke. If such conditions can be determined at an early stage, aggressive treatment can prevent possibly-fatal events from ever occurring, diaDexus claims.
Burrill & Co., Rho Ventures, Bain Capital's Brookside Fund and Mosaix Ventures. It last raised funds at the beginning of 2007 amounting to $40 million.